The Enhanced Games — tech’s steroid extravaganza — didn’t pay off, as company posts $60 million loss

In May, Las Vegas witnessed the Enhanced Games, an unconventional sports competition that allowed athletes to compete under the use of performance-enhancing drugs usually prohibited in professional sports. The event was organized by a telehealth company backed by high-profile investors such as Peter Thiel and staffed by experts from the cryptocurrency, artificial intelligence, and biotech sectors.

Despite initial hype, the games failed to deliver significant surprises, with only one world record being set during the competition, in the swimming event.

However, the Enhanced Games did not end on a positive note. The Enhanced Group, the company behind the event, reported a significant loss of nearly $62 million in its second-quarter earnings, with a substantial portion of the loss stemming from the games themselves. The company, founded in 2023 and initially valued at $1.2 billion, primarily earns revenue through personalized health treatments dispensed through a digital telehealth platform.

These treatments include FDA-approved products like peptides, testosterone injections, GLP-1s for weight loss, and other similar substances.

While the Enhanced Games proved to be a commercial failure, the company's core business continued to face uncertainties. The $17.7 million revenue generated in the second quarter was mainly attributed to sponsorships linked to the games, not the telehealth sector. Consequently, the report casts doubt on the executives' claims that the games would become an annual event.

Enhanced may be planning a shift in strategy, as evidenced by the launch of a new online series, Enhanced Breakers, which is projected to operate at a fraction of the cost of a full Games event while maintaining engagement among athletes, audiences, sponsors, and performance medicine enthusiasts year-round.

Despite the challenges faced by the Enhanced Games, the industry surrounding it is experiencing growth. The peptide business, in particular, is booming, fueled by recent regulatory changes implemented by the Trump administration's Food and Drug Administration. The FDA reclassified several substances previously residing in a legally ambiguous space, signaling a potential shift towards deregulation.

This development is further supported by the U.S. Department of Health and Human Services, which is overseen by Robert F. Kennedy Jr., known for his unconventional views on health. Despite criticisms from health professionals, the industry's momentum remains undeterred.

Notably, Silicon Valley serves as a hub for peptide startups, with companies like Superpower and Noho Labs capitalizing on the tech industry's fascination with biohacking and trendy health supplements. However, the rapid growth of the sector is outpacing regulatory frameworks, leaving state governments struggling to keep up with the evolving schemes governing the industry.